At the news
? NEUTRALIMPACT 3/10 144 filed Apr 1, 2026 at 16:42 ET
Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 to report the proposed sale of 14,640 shares, following a series of recent 10b5-1 plan sales totaling over $12.1M in the past month. This filing is part of an ongoing, pre-arranged selling plan and not an isolated event.
- Jeremy Chadwick, an officer of Kymera Therapeutics, filed Form 144 to propose the sale of 14,640 common shares.
- The sale is part of a 10b5-1 trading plan, with recent sales already executed: 7,600 shares (~$649K) on 03/31/2026, 24,727 shares (~$1.98M) on 03/25/2026, 91,250 shares (~$7.06M) on 03/23/2026, and others totaling over $12.1M in the past month.
- The proposed sale proceeds will be received in cash and are not tied to any new insider decision, as 10b5-1 plans are pre-scheduled.
- Recent insider activity shows 4 sell transactions in the last 30 days totaling $3.8M, consistent with this pattern.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access